AI Verdict
RARE has stronger fundamentals based on our AI analysis.
RARE vs RANI Fundamental Comparison
| Metric | RARE | RANI |
|---|---|---|
| Revenue | $673.0M | $1.6M |
| Net Income | $-575.0M | $-29.7M |
| Net Margin | -85.4% | -1,817.1% |
| ROE | N/A | -89.9% |
| ROA | -37.5% | -50.6% |
| Current Ratio | 2.48x | 4.21x |
| Debt/Equity | N/A | 0.00x |
| EPS | $-5.83 | $-0.45 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RARE vs RANI: Frequently Asked Questions
Is RARE or RANI a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RARE has stronger fundamentals. RARE is rated SELL (72% confidence) while RANI is rated SELL (48% confidence). This is not investment advice.
How does RARE compare to RANI fundamentally?
Ultragenyx Pharmaceutical Inc. has ROE of N/A vs Rani Therapeutics Holdings, Inc.'s -89.9%. Net margins are -85.4% vs -1,817.1% respectively.
Which stock pays higher dividends, RARE or RANI?
RARE has a dividend yield of N/A or no dividend while RANI has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RARE or RANI for long term?
For long-term investing, consider that RARE has SELL rating with 72% confidence, while RANI has SELL rating with 48% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RARE vs RANI?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RARE vs RANI, the AI consensus favors RARE based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.